Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Total Liabilities

Last Annual Value

34.14M

3-Year CAGR

-1%

5-Year CAGR

-22%

10-Year CAGR

-13%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Total Liabilities

NAUT · NASDAQ
CompanyTotal Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
34.14M
-5.3%-0.4%N/A 
23.66M
-8.7%-9.1%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.41M
-16.5%3.7%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
113.26M
-0.4%-7.2%N/A
57.16M
-27.6%-19.1%29.4%
5.10M
-3.4%-52.8%N/A
13.50M
4.0%4.7%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
504.66M
3.0%3.8%9.9%
14.12M
9.7%12.4%N/A
8.02M
24.1%21.5%N/A
6.42M
2.7%-2.1%17.0%
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58